oral glp 1 agonist for weight loss GLP-1s Loss: What You Need to Know Novel oral GLP-1 receptor agonist

The incretin agonist I-M-150846 revealed a complete loss of function at GLP-1R while retaining GIPR activity (Table 1)

In addition to heterogeneity, potential sources of bias must be considered, particularly in observational studies assessing treatment persistence and real-world effectiveness

Expanding therapeutic indications beyond diabetes into obesity treatment multiplies the addressable market size

Warning signs requiring prompt evaluation include: Rectal bleeding or blood in stool Unexplained weight loss (beyond expected medication effect) Persistent change in bowel habits lasting more than a few weeks New-onset abdominal pain that differs from typical GLP-1 side effects Iron-deficiency anemia These symptoms warrant investigation regardless of medication use, as they may indicate various gastrointestinal conditions requiring diagnosis